Table 3.
Cardiovascular disease risk factor and lifestyle data
| CVD Risk factors | Patient group | Control group | Significance |
|---|---|---|---|
| Smoking status (+) |
58/95 (61%) |
8/27 (30%) |
~2 fold increase |
| Diabetes mellitus (+) |
6/95 (6%) |
1/27 (0.04%) |
>100 fold increase |
| Body Mass Index (BMI) |
32.45 ± 0.62 |
27.53 ± 0.86 |
0.002*** |
| Hypertension treatment |
24/95 (25%) |
6/27 (22%) |
no change |
| Systolic blood pressure |
123 ± 1.5 |
122 ± 0.16 |
0.5675 |
| Total cholesterol |
5.08 ± 0.13 |
5.11 ± 0.16 |
0.9117 |
| Framingham (%) | 7.01 ± 0.62 | 5.31 ± 0.89 | 0.1797 |
Cardiovascular disease risk factors data and Framingham-10-year (%) risk of cardiovascular disease incident of patients treated with clozapine (n = 97) and healthy control subjects (n = 27). Data expressed as mean ± SEM. Statistical analysis was performed using Student’s unpaired T test (two-tailed). The significance levels (or alpha levels) were set at p < 0.001***.